NO312296B1 - Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat - Google Patents
Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat Download PDFInfo
- Publication number
- NO312296B1 NO312296B1 NO19985531A NO985531A NO312296B1 NO 312296 B1 NO312296 B1 NO 312296B1 NO 19985531 A NO19985531 A NO 19985531A NO 985531 A NO985531 A NO 985531A NO 312296 B1 NO312296 B1 NO 312296B1
- Authority
- NO
- Norway
- Prior art keywords
- benzo
- ylmethyl
- oxazin
- piperazin
- compound according
- Prior art date
Links
- -1 Benzoxazinone-dopamine Chemical compound 0.000 title claims abstract description 15
- 229940124243 Dopamine D4 receptor antagonist Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001408 amides Chemical class 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims abstract description 9
- 239000000651 prodrug Substances 0.000 claims abstract description 8
- 229940002612 prodrug Drugs 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 28
- 208000028017 Psychotic disease Diseases 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical group C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- GPGUDXIKRCJQNT-UHFFFAOYSA-N 4-[4-[(3-oxo-4h-1,4-benzoxazin-6-yl)methyl]piperazin-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 GPGUDXIKRCJQNT-UHFFFAOYSA-N 0.000 claims description 3
- NFRIERLNKMVOKN-UHFFFAOYSA-N 6-[(4-phenylpiperazin-1-yl)methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1CN(CC1)CCN1C1=CC=CC=C1 NFRIERLNKMVOKN-UHFFFAOYSA-N 0.000 claims description 3
- RCWYEZYTOVCNOJ-UHFFFAOYSA-N 6-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 RCWYEZYTOVCNOJ-UHFFFAOYSA-N 0.000 claims description 3
- RKZVRIHTYWJVDD-UHFFFAOYSA-N 6-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 RKZVRIHTYWJVDD-UHFFFAOYSA-N 0.000 claims description 3
- CDXSZIGVTVIYPC-UHFFFAOYSA-N 7-[(4-phenylpiperazin-1-yl)methyl]-4h-1,4-benzoxazin-3-one Chemical compound C=1C=C2NC(=O)COC2=CC=1CN(CC1)CCN1C1=CC=CC=C1 CDXSZIGVTVIYPC-UHFFFAOYSA-N 0.000 claims description 3
- VYJSEMNZGPEKAE-UHFFFAOYSA-N 7-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 VYJSEMNZGPEKAE-UHFFFAOYSA-N 0.000 claims description 3
- LILUJJCOIBEHSU-UHFFFAOYSA-N 7-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C)=CC=C1N1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 LILUJJCOIBEHSU-UHFFFAOYSA-N 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- NRQPGKHEEBJOCT-UHFFFAOYSA-N 2-[4-[(3-oxo-4h-1,4-benzoxazin-6-yl)methyl]piperazin-1-yl]benzonitrile Chemical compound C1=C2NC(=O)COC2=CC=C1CN(CC1)CCN1C1=CC=CC=C1C#N NRQPGKHEEBJOCT-UHFFFAOYSA-N 0.000 claims description 2
- URZGAIFKYPHOKG-UHFFFAOYSA-N 6-[[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2SC(N3CCN(CC3)CC3=CC=C4OCC(NC4=C3)=O)=NC2=C1 URZGAIFKYPHOKG-UHFFFAOYSA-N 0.000 claims description 2
- IKPCGAGVKSYPGV-UHFFFAOYSA-N 6-[[4-(1,3-thiazol-2-yl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)COC2=CC=C1CN(CC1)CCN1C1=NC=CS1 IKPCGAGVKSYPGV-UHFFFAOYSA-N 0.000 claims description 2
- VVOSVZFUEQAUTE-UHFFFAOYSA-N 6-[[4-(2-chloro-4-methylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound ClC1=CC(C)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 VVOSVZFUEQAUTE-UHFFFAOYSA-N 0.000 claims description 2
- VXIJULJNEBZDDL-UHFFFAOYSA-N 6-[[4-(2-chlorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound ClC1=CC=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 VXIJULJNEBZDDL-UHFFFAOYSA-N 0.000 claims description 2
- XXASGLPIGNTUBG-UHFFFAOYSA-N 6-[[4-(3,4-dichlorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 XXASGLPIGNTUBG-UHFFFAOYSA-N 0.000 claims description 2
- UROZVASCLWFZOW-UHFFFAOYSA-N 6-[[4-(3,4-dimethylphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C(C)C(C)=CC=C1C1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 UROZVASCLWFZOW-UHFFFAOYSA-N 0.000 claims description 2
- FDYRPFOMRUNDJD-UHFFFAOYSA-N 6-[[4-(3,5-dimethylphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC(C)=CC(N2CCN(CC=3C=C4NC(=O)COC4=CC=3)CC2)=C1 FDYRPFOMRUNDJD-UHFFFAOYSA-N 0.000 claims description 2
- CZSXHWSVDAMAMN-UHFFFAOYSA-N 6-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound ClC1=CC=CC(N2CCN(CC=3C=C4NC(=O)COC4=CC=3)CC2)=C1 CZSXHWSVDAMAMN-UHFFFAOYSA-N 0.000 claims description 2
- XJCFFIUVQKFBHI-UHFFFAOYSA-N 6-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 XJCFFIUVQKFBHI-UHFFFAOYSA-N 0.000 claims description 2
- CKAQTYOFZFLRAG-UHFFFAOYSA-N 6-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(F)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 CKAQTYOFZFLRAG-UHFFFAOYSA-N 0.000 claims description 2
- MOWGNBXIJRPPMR-UHFFFAOYSA-N 6-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 MOWGNBXIJRPPMR-UHFFFAOYSA-N 0.000 claims description 2
- OCMQSLHFQZYSMB-UHFFFAOYSA-N 6-[[4-(4-methoxyphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OC)=CC=C1C1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 OCMQSLHFQZYSMB-UHFFFAOYSA-N 0.000 claims description 2
- BHPFUCZWSRDHAY-UHFFFAOYSA-N 6-[[4-(4-methylphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C)=CC=C1C1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 BHPFUCZWSRDHAY-UHFFFAOYSA-N 0.000 claims description 2
- XMKGKKQBGKDTBK-UHFFFAOYSA-N 6-[[4-(5-methylpyridin-2-yl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound N1=CC(C)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 XMKGKKQBGKDTBK-UHFFFAOYSA-N 0.000 claims description 2
- ZFXFEXWZNAKUBL-UHFFFAOYSA-N 7-[(4-naphthalen-2-ylpiperazin-1-yl)methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC=CC2=CC(N3CCN(CC3)CC=3C=C4OCC(NC4=CC=3)=O)=CC=C21 ZFXFEXWZNAKUBL-UHFFFAOYSA-N 0.000 claims description 2
- PLLZRTCZPQQFEO-UHFFFAOYSA-N 7-[(4-phenylpiperidin-1-yl)methyl]-4h-1,4-benzoxazin-3-one Chemical compound C=1C=C2NC(=O)COC2=CC=1CN(CC1)CCC1C1=CC=CC=C1 PLLZRTCZPQQFEO-UHFFFAOYSA-N 0.000 claims description 2
- MEPWUVRGPZZAFY-UHFFFAOYSA-N 7-[[4-(3,4-dimethylphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=C(C)C(C)=CC=C1C1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 MEPWUVRGPZZAFY-UHFFFAOYSA-N 0.000 claims description 2
- UFFHNEZNXKJHFB-UHFFFAOYSA-N 7-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 UFFHNEZNXKJHFB-UHFFFAOYSA-N 0.000 claims description 2
- CHPZSVIXPWGKFQ-UHFFFAOYSA-N 7-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 CHPZSVIXPWGKFQ-UHFFFAOYSA-N 0.000 claims description 2
- ZNVJBKVJJHNRRV-UHFFFAOYSA-N 7-[[4-(4-methoxyphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OC)=CC=C1C1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 ZNVJBKVJJHNRRV-UHFFFAOYSA-N 0.000 claims description 2
- YRTKLZDQSKUCQM-UHFFFAOYSA-N 7-[[4-(4-methylphenyl)piperidin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C)=CC=C1C1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 YRTKLZDQSKUCQM-UHFFFAOYSA-N 0.000 claims description 2
- PHOCTWVGFOPTKO-UHFFFAOYSA-N 7-[[4-(5-methylpyridin-2-yl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound N1=CC(C)=CC=C1N1CCN(CC=2C=C3OCC(=O)NC3=CC=2)CC1 PHOCTWVGFOPTKO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- AONOATOEMKXSHK-UHFFFAOYSA-N 6-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC=3C=C4NC(=O)COC4=CC=3)CC2)=C1 AONOATOEMKXSHK-UHFFFAOYSA-N 0.000 claims 1
- DDNPFSNFHUDIIU-UHFFFAOYSA-N 6-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 DDNPFSNFHUDIIU-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 102000003962 Dopamine D4 receptors Human genes 0.000 abstract description 3
- 108090000357 Dopamine D4 receptors Proteins 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 108050004812 Dopamine receptor Proteins 0.000 description 6
- 102000015554 Dopamine receptor Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- XJVJSJJDAJQPRJ-UHFFFAOYSA-N 2-chloro-n-(4-formyl-2-hydroxyphenyl)acetamide Chemical compound OC1=CC(C=O)=CC=C1NC(=O)CCl XJVJSJJDAJQPRJ-UHFFFAOYSA-N 0.000 description 3
- GEBVVLQOUZTAQP-UHFFFAOYSA-N 2-chloro-n-(5-formyl-2-hydroxyphenyl)acetamide Chemical compound OC1=CC=C(C=O)C=C1NC(=O)CCl GEBVVLQOUZTAQP-UHFFFAOYSA-N 0.000 description 3
- FPPZKSNLDCNYFG-UHFFFAOYSA-N 5-(1,3-dioxan-2-yl)-2-nitrophenol Chemical compound C1=C([N+]([O-])=O)C(O)=CC(C2OCCCO2)=C1 FPPZKSNLDCNYFG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- SFLNVAVCCYTHCQ-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)piperazine Chemical compound C1=C(C)C(C)=CC=C1N1CCNCC1 SFLNVAVCCYTHCQ-UHFFFAOYSA-N 0.000 description 2
- ONEYFZXGNFNRJH-UHFFFAOYSA-N 1-(4-methylphenyl)piperazine Chemical compound C1=CC(C)=CC=C1N1CCNCC1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- VHKABBARGFUYOF-UHFFFAOYSA-N 3-oxo-4h-1,4-benzoxazine-6-carbaldehyde Chemical compound O1CC(=O)NC2=CC(C=O)=CC=C21 VHKABBARGFUYOF-UHFFFAOYSA-N 0.000 description 2
- YYWWHYLCSGBYKQ-UHFFFAOYSA-N 4-[[4-(2-methylphenyl)piperazin-1-yl]methyl]-2-nitrophenol Chemical compound CC1=CC=CC=C1N1CCN(CC=2C=C(C(O)=CC=2)[N+]([O-])=O)CC1 YYWWHYLCSGBYKQ-UHFFFAOYSA-N 0.000 description 2
- YTHJCZRFJGXPTL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1[N+]([O-])=O YTHJCZRFJGXPTL-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 125000006824 (C1-C6) dialkyl amine group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RFOOCTIUWMGNJG-UHFFFAOYSA-N 2-nitro-4-[(4-phenylpiperazin-1-yl)methyl]phenol Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1CN1CCN(C=2C=CC=CC=2)CC1 RFOOCTIUWMGNJG-UHFFFAOYSA-N 0.000 description 1
- AUBBVPIQUDFRQI-UHFFFAOYSA-N 3-hydroxy-4-nitrobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1[N+]([O-])=O AUBBVPIQUDFRQI-UHFFFAOYSA-N 0.000 description 1
- PMWMYJAFFRJOEI-UHFFFAOYSA-N 3-oxo-4a,5-dihydro-4h-1,4-benzoxazine-7-carbaldehyde Chemical compound N1C(=O)COC2=CC(C=O)=CCC21 PMWMYJAFFRJOEI-UHFFFAOYSA-N 0.000 description 1
- YCIZZCSWMNUTGR-UHFFFAOYSA-N 3-oxo-4h-1,4-benzoxazine-7-carbaldehyde Chemical compound N1C(=O)COC2=CC(C=O)=CC=C21 YCIZZCSWMNUTGR-UHFFFAOYSA-N 0.000 description 1
- BTPRJICVNPYLTP-UHFFFAOYSA-N 4-(1,3-dioxan-2-yl)-2-nitrophenol Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1C1OCCCO1 BTPRJICVNPYLTP-UHFFFAOYSA-N 0.000 description 1
- UGGDHKASBRILQW-UHFFFAOYSA-N 4-piperazin-1-ylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1CCNCC1 UGGDHKASBRILQW-UHFFFAOYSA-N 0.000 description 1
- IUPDOAUDWJKQKD-UHFFFAOYSA-N 6-[(4-naphthalen-2-ylpiperazin-1-yl)methyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC=CC2=CC(N3CCN(CC3)CC3=CC=C4OCC(NC4=C3)=O)=CC=C21 IUPDOAUDWJKQKD-UHFFFAOYSA-N 0.000 description 1
- HYPGXKWWXBYXDB-UHFFFAOYSA-N 6-[[4-(4,5-dimethyl-1,3-thiazol-2-yl)piperazin-1-yl]methyl]-4h-1,4-benzoxazin-3-one Chemical compound S1C(C)=C(C)N=C1N1CCN(CC=2C=C3NC(=O)COC3=CC=2)CC1 HYPGXKWWXBYXDB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1838396P | 1996-05-29 | 1996-05-29 | |
US4020897P | 1997-03-06 | 1997-03-06 | |
PCT/US1997/008524 WO1997045419A1 (en) | 1996-05-29 | 1997-05-20 | Benzoxazinone dopamine d4 receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
NO985531L NO985531L (no) | 1998-11-27 |
NO985531D0 NO985531D0 (no) | 1998-11-27 |
NO312296B1 true NO312296B1 (no) | 2002-04-22 |
Family
ID=26691052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19985531A NO312296B1 (no) | 1996-05-29 | 1998-11-27 | Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP0906294B1 (hu) |
JP (1) | JP2000511534A (hu) |
KR (1) | KR20000016151A (hu) |
CN (1) | CN1074764C (hu) |
AR (1) | AR008372A1 (hu) |
AT (1) | ATE231846T1 (hu) |
AU (1) | AU731104B2 (hu) |
BG (1) | BG64049B1 (hu) |
BR (1) | BR9709630A (hu) |
CA (1) | CA2253406A1 (hu) |
CO (1) | CO4940505A1 (hu) |
CZ (1) | CZ384698A3 (hu) |
DE (1) | DE69718786T2 (hu) |
DK (1) | DK0906294T3 (hu) |
EA (1) | EA001486B1 (hu) |
EE (1) | EE03686B1 (hu) |
ES (1) | ES2191180T3 (hu) |
GE (1) | GEP20012389B (hu) |
HK (1) | HK1019737A1 (hu) |
HN (1) | HN1997000075A (hu) |
HR (1) | HRP970301B1 (hu) |
HU (1) | HUP9903758A3 (hu) |
ID (1) | ID17266A (hu) |
IL (1) | IL126895A (hu) |
NO (1) | NO312296B1 (hu) |
NZ (1) | NZ332737A (hu) |
PA (1) | PA8431101A1 (hu) |
PE (1) | PE69398A1 (hu) |
PL (1) | PL330195A1 (hu) |
PT (1) | PT906294E (hu) |
RO (1) | RO120845B1 (hu) |
SI (1) | SI0906294T1 (hu) |
SK (1) | SK282703B6 (hu) |
SV (1) | SV1997000047A (hu) |
TW (1) | TW542833B (hu) |
UY (1) | UY24569A1 (hu) |
WO (1) | WO1997045419A1 (hu) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6177422B1 (en) | 1996-05-29 | 2001-01-23 | Warner-Lambert Company | Benzoxazinone dopamine D4 receptor antagonists |
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
AU4832699A (en) * | 1998-06-30 | 2000-01-17 | Neurogen Corporation | 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands |
US6291463B1 (en) | 1998-06-30 | 2001-09-18 | Neurogen Corporation | 1-(Benzothiazol-2-yl)-4-(1-phenylmethyl) piperazines: dopamine receptor subtype specific ligands |
CA2336089A1 (en) * | 1998-06-30 | 2000-01-06 | Neurogen Corporation | 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands |
US6177566B1 (en) | 1998-06-30 | 2001-01-23 | Neurogen Corporation | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands |
DE19844291A1 (de) * | 1998-09-18 | 2000-03-23 | Schering Ag | Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln |
GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
EP1330460B1 (en) | 2000-10-26 | 2007-03-21 | Smithkline Beecham Plc | Benzoxazinone derivatives, their preparation and use |
GB0203804D0 (en) | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
GB0209244D0 (en) * | 2002-04-23 | 2002-06-05 | Glaxo Group Ltd | Compounds |
GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
ES2232292B1 (es) * | 2003-07-30 | 2006-11-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos. |
CN100455573C (zh) * | 2005-11-11 | 2009-01-28 | 华东理工大学 | 一种制备1,4-苯并噁唑嗪-3-酮化合物的微波合成方法 |
KR200482995Y1 (ko) | 2015-08-19 | 2017-03-23 | 이현진 | 물 공급부를 구비하는 얼음 트레이 |
CA3215823A1 (en) * | 2021-04-23 | 2022-10-27 | Peng Gao | Heterocyclic derivative inhibitor and preparation method therefor and application thereof |
WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023207283A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Compounds as parp1 inhibitiors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613598A (en) * | 1984-03-13 | 1986-09-23 | Mitsubishi Chemical Industries Limited | Piperazine derivatives and their acid addition salts |
EP0233728A1 (en) * | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazine derivatives their production and use |
JPH07509705A (ja) * | 1992-08-06 | 1995-10-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ドーパミンd3レセプター拮抗薬用5−(2−オキシフェニル)−ピロール誘導体 |
-
1997
- 1997-05-20 PT PT97925651T patent/PT906294E/pt unknown
- 1997-05-20 EP EP97925651A patent/EP0906294B1/en not_active Expired - Lifetime
- 1997-05-20 GE GEAP19974623A patent/GEP20012389B/en unknown
- 1997-05-20 NZ NZ332737A patent/NZ332737A/en unknown
- 1997-05-20 JP JP09542647A patent/JP2000511534A/ja not_active Ceased
- 1997-05-20 SI SI9730482T patent/SI0906294T1/xx unknown
- 1997-05-20 PL PL97330195A patent/PL330195A1/xx unknown
- 1997-05-20 HU HU9903758A patent/HUP9903758A3/hu unknown
- 1997-05-20 DK DK97925651T patent/DK0906294T3/da active
- 1997-05-20 RO RO98-01622A patent/RO120845B1/ro unknown
- 1997-05-20 SK SK1627-98A patent/SK282703B6/sk unknown
- 1997-05-20 AU AU30727/97A patent/AU731104B2/en not_active Ceased
- 1997-05-20 DE DE69718786T patent/DE69718786T2/de not_active Expired - Fee Related
- 1997-05-20 ES ES97925651T patent/ES2191180T3/es not_active Expired - Lifetime
- 1997-05-20 EA EA199800987A patent/EA001486B1/ru not_active IP Right Cessation
- 1997-05-20 EE EE9800417A patent/EE03686B1/xx not_active IP Right Cessation
- 1997-05-20 WO PCT/US1997/008524 patent/WO1997045419A1/en not_active Application Discontinuation
- 1997-05-20 KR KR1019980709719A patent/KR20000016151A/ko not_active Application Discontinuation
- 1997-05-20 CZ CZ983846A patent/CZ384698A3/cs unknown
- 1997-05-20 BR BR9709630A patent/BR9709630A/pt not_active Application Discontinuation
- 1997-05-20 CN CN97195015A patent/CN1074764C/zh not_active Expired - Fee Related
- 1997-05-20 CA CA002253406A patent/CA2253406A1/en not_active Abandoned
- 1997-05-20 IL IL12689597A patent/IL126895A/en not_active IP Right Cessation
- 1997-05-20 AT AT97925651T patent/ATE231846T1/de not_active IP Right Cessation
- 1997-05-22 HN HN1997000075A patent/HN1997000075A/es unknown
- 1997-05-27 AR ARP970102249A patent/AR008372A1/es unknown
- 1997-05-28 ID IDP971778A patent/ID17266A/id unknown
- 1997-05-28 UY UY24569A patent/UY24569A1/es not_active Application Discontinuation
- 1997-05-28 CO CO97029474A patent/CO4940505A1/es unknown
- 1997-05-28 TW TW086107221A patent/TW542833B/zh active
- 1997-05-28 SV SV1997000047A patent/SV1997000047A/es not_active Application Discontinuation
- 1997-05-28 PE PE1997000432A patent/PE69398A1/es not_active Application Discontinuation
- 1997-05-28 PA PA19978431101A patent/PA8431101A1/es unknown
- 1997-05-29 HR HR970301A patent/HRP970301B1/xx not_active IP Right Cessation
-
1998
- 1998-11-26 BG BG102959A patent/BG64049B1/bg unknown
- 1998-11-27 NO NO19985531A patent/NO312296B1/no not_active IP Right Cessation
-
1999
- 1999-10-28 HK HK99104867A patent/HK1019737A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018214105B2 (en) | Pyridone Amides as Modulators of Sodium Channels | |
NO312296B1 (no) | Benzoksazinon-dopamin-D4-reseptor-antagonister, anvendelse derav, samt farmasöytisk preparat | |
CA2898650C (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
CA2898653C (en) | Amides as modulators of sodium channels | |
EP1917248B1 (de) | 1-acyldihydropyrazolderivate | |
EP2150551A1 (de) | 2-oxo-3-benzyl-benzoxazol-2-one derivate und verwandte verbindungen als met-kinase inhibitoren zur behandlung von tumoren | |
WO2007057092A1 (de) | Substituierte 5-phenyl-3,6-dihydro-2-oxo-6h-[1,3,4]thiadiazine | |
DE69007891T2 (de) | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one und -thione und ihre Verwendung bei der AIDS-Vorbeugung oder -Behandlung. | |
IL191361A (en) | Compounds Containing 6,3-Dihydro-2-Oxo-H6- [1,3,4] Thyadiazines | |
JP5404607B2 (ja) | 抗rnaウイルス作用を有するアニリン誘導体 | |
CA2929188C (en) | Quinazoline derivatives as tam family kinase inhibitors | |
NO309477B1 (no) | Nye heterocykliske aminometylforbindelser, fremgangsmåte ved fremstilling av dem og farmasöytiske sammensetninger som inneholder dem | |
EP2373635A1 (de) | Benzothiazolonderivate | |
US6177422B1 (en) | Benzoxazinone dopamine D4 receptor antagonists | |
AU653444B2 (en) | Thiadiazinone | |
US5916914A (en) | Compounds and method of treating psychosis and schizophrenia | |
US5945421A (en) | Dopamine D4 receptor antagonists | |
US5922719A (en) | Coumarin dopamine D4 receptor antagonists | |
US6087364A (en) | Dopamine D4 receptor antagonists | |
CZ8096A3 (en) | Derivative of 3-alkoxycarbonylthiadiazinone, process of its preparation and pharmaceutical composition containing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |